Sodium Bicarbonate Dosing Showed No Kidney Benefit
Higher bicarbonate targets failed to slow kidney function decline in a recent two-year clinical study.
Updated on Oct. 10, 2026 in Nutrition
Live Poll
Do you trust established medical treatment protocols when new research shows mixed results?
A randomized trial of 58 patients with chronic kidney disease found no significant difference in the decline of kidney function when targeting higher versus lower serum bicarbonate levels. Researchers observed this outcome after 104 weeks of monitoring.
Why it matters
The study suggests that adjusting bicarbonate treatment strategies may not alter the progression of chronic kidney disease as previously hypothesized. This finding clarifies the clinical role of sodium bicarbonate supplementation in managing long-term kidney health.
In an open-label randomized trial of 58 patients with stage 3 to 4 chronic kidney disease, researchers compared outcomes for participants targeting 20 mmol/L versus 24 mmol/L of serum bicarbonate. After 104 weeks, the difference in the rate of estimated glomerular filtration rate (eGFR) decline between the groups was not statistically significant.
The details
The study tested whether boosting serum bicarbonate through a median daily dose of 6.7 grams of sodium bicarbonate could buffer metabolic acidosis and preserve kidney function. While roughly 70 percent of participants successfully reached their respective bicarbonate targets, the higher concentration did not demonstrably slow the loss of eGFR. Researchers monitored participants over 104 weeks to track these physiological changes.
Timeline
Week 47: Researchers measured a mean serum bicarbonate difference of 3.57 mmol/L.
104 weeks: Total duration of the patient follow-up period.
Health Landscape
This research sits within the ongoing effort to define optimal metabolic targets for patients with stage 3 to 4 chronic kidney disease. It contributes to the evolving clinical consensus on whether systemic buffering therapy provides a measurable protective effect for renal function.
If you are currently managing stage 3 or 4 chronic kidney disease, these findings suggest that aggressive bicarbonate supplementation targets may not offer the kidney-preservation benefits previously hoped for. It is important to discuss your current treatment goals and any supplement use with your nephrologist.
The takeaway
This trial indicates that higher serum bicarbonate targets do not necessarily prevent faster kidney function decline in stage 3 or 4 chronic kidney disease. Patients should maintain open communication with their medical team regarding the necessity and efficacy of any metabolic interventions.
Further reading
For more on how diet and clinical management intersect with renal health, visit Nutrition.
More information
View the complete results of this study in the peer-reviewed research article.
Source note: This article includes information reported by Nature.
Live Poll
Do you trust established medical treatment protocols when new research shows mixed results?
